Detection of the secondary, low-affinity β1-adrenoceptor site in living cells using the fluorescent CGP 12177 derivative BODIPY-TMR-CGP

British Journal of Pharmacology

Volumn 171, Issue 23, 2014, Pages 5431-5445

  Gherbi, K ^a   Briddon, S J ^a   Hill, S J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; ALKALINE PHOSPHATASE PLACENTA ISOENZYME; BENZIMIDAZOLE DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BORDIFLUOROPYRROMETHANE TETRAMETHYLRHODAMINE; FLUORESCENT DYE; UNCLASSIFIED DRUG; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BODIPY-TMR-CGP; BORON DERIVATIVE; CYCLIC AMP; CYCLOPENTANE DERIVATIVE; MEMBRANE PROTEIN; PDZK1IP1 PROTEIN, HUMAN; PROPANOLAMINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING SITE; CHO CELL LINE; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR BINDING; REPORTER GENE; ANIMAL; CRICETULUS; DNA RESPONSIVE ELEMENT; GENETICS; HUMAN; METABOLISM;

ADRENERGIC BETA-1 RECEPTOR AGONISTS; ANIMALS; BORON COMPOUNDS; CHO CELLS; CRICETULUS; CYCLIC AMP; CYCLOPENTANES; FLUORESCENT DYES; GENES, REPORTER; HUMANS; MEMBRANE PROTEINS; PROPANOLAMINES; PYRROLES; RECEPTORS, ADRENERGIC, BETA-1; RESPONSE ELEMENTS;

EID: 84925949909     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12858     Document Type: Article

References (40)

1. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The concise guide to pharmacology 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Baker JG, (2005). Site of action of beta-ligands at the human β1-adrenoceptor. J Pharmacol Exp Ther 313: 1163-1171.
3. Baker JG, Hall IP, Hill SJ, (2002). Pharmacological characterization of CGP 12177 at the human β2-adrenoceptor. Br J Pharmacol 137: 400-408.
4. Baker JG, Hall IP, Hill SJ, (2003a). Agonist actions of 'beta-blockers' provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor. Mol Pharmacol 63: 1312-1321.
5. Baker JG, Hall IP, Hill SJ, (2003b). Pharmacology and direct visualisation of BODIPY-TMR-CGP: a long-acting fluorescent β2-adrenoceptor agonist. Br J Pharmacol 139: 232-242.
6. Baker JG, Proudman RG, Hawley NC, Fischer PM, Hill SJ, (2008). Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human β1-adrenoceptor. Mol Pharmacol 74: 1246-1260.
7. Baker JG, Middleton R, Adams L, May LT, Briddon SJ, Kellam B, et al. (2010). Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands. Br J Pharmacol 159: 772-786.
8. Baker JG, Proudman RG, Hill SJ, (2014). Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor. Mol Pharmacol 85: 811-829.
9. Becker A, Hessenius C, Licha K, Ebert B, Sukowski U, Semmler W, et al. (2001). Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 19: 327-331.
10. Briddon SJ, Middleton RJ, Cordeaux Y, Flavin FM, Weinstein JA, George MW, et al. (2004). Quantitative analysis of the formation and diffusion of A1-adenosine receptor-antagonist complexes in single living cells. Proc Natl Acad Sci U S A 101: 4673-4678.
11. Daly CJ, Ross RA, Whyte J, Henstridge CM, Irving AJ, McGrath JC, (2010). Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br J Pharmacol 159: 787-796.
12. Dubois EA, Somsen GA, van den Bos JC, Janssen AG, Boer GJ, Batink HD, et al. (1996). Pharmacologic characterization in vitro and in vivo of iodine 123-labeled derivatives of the beta-adrenoceptor antagonist CGP12177, designed for the imaging of cardiac beta-receptors. J Nucl Cardiol 3: 242-252.
13. Hara T, Hirasawa A, Sun Q, Koshimizu TA, Itsubo C, Sadakane K, et al. (2009). Flow cytometry-based binding assay for GPR40 (FFAR1; free fatty acid receptor 1). Mol Pharmacol 75: 85-91.
14. Hopkinson HE, Latif ML, Hill SJ, (2000). Non-competitive antagonism of β2-agonist-mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active β2-adrenoceptors. Br J Pharmacol 131: 124-130.
15. Hulme EC, Trevethick MA, (2010). Ligand binding assays at equilibrium: validation and interpretation. Br J Pharmacol 161: 1219-1237.
16. Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, Kaumann AJ, (2003). Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the β1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol 368: 496-503.
17. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ, (2004). Binding of (-)-[3H]-CGP12177 at two sites in recombinant human β1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol 369: 525-532.
18. Kaumann AJ, Molenaar P, (2008). The low-affinity site of the β1-adrenoceptor and its relevance to cardiovascular pharmacology. Pharmacol Ther 118: 303-336.
19. Kaumann AJ, Engelhardt S, Hein L, Molenaar P, Lohse M, (2001). Abolition of (-)-CGP 12177-evoked cardiostimulation in double β1/β2-adrenoceptor knockout mice. Obligatory role of β1-adrenoceptors for putative β4-adrenoceptor pharmacology. Naunyn Schmiedebergs Arch Pharmacol 363: 87-93.
20. Kenakin TP, Beek D, (1984). The measurement of the relative efficacy of agonists by selective potentiation of tissue responses: studies with isoprenaline and prenalterol in cardiac tissue. J Auton Pharmacol 4: 153-159.
21. Kompa AR, Summers RJ, (1999). Desensitization and resensitization of β1- and putative β4-adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure. Br J Pharmacol 128: 1399-1406.
22. Konkar AA, Zhai Y, Granneman JG, (2000a). β1-adrenergic receptors mediateβ3-adrenergic-independent effects of CGP 12177 in brown adipose tissue. Mol Pharmacol 57: 252-258.
23. Konkar AA, Zhu Z, Granneman JG, (2000b). Aryloxypropanolamine and catecholamine ligand interactions with the β1-adrenergic receptor: evidence for interaction with distinct conformations of β1-adrenergic receptors. J Pharmacol Exp Ther 294: 923-932.
24. Leff P, Dougall IG, Harper D, (1993). Estimation of partial agonist affinity by interaction with a full agonist: a direct operational model-fitting approach. Br J Pharmacol 110: 239-244.
25. Lew MJ, Angus JA, (1995). Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 16: 328-337.
26. Lowe MD, Lynham JA, Grace AA, Kaumann AJ, (2002). Comparison of the affinity of beta-blockers for two states of the β1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol 135: 451-461.
27. May LT, Self TJ, Briddon SJ, Hill SJ, (2010). The effect of allosteric modulators on the kinetics of agonist-G protein-coupled receptor interactions in single living cells. Mol Pharmacol 78: 511-523.
28. Middleton RJ, Kellam B, (2005). Fluorophore-tagged GPCR ligands. Curr Opin Chem Biol 9: 517-525.
29. Molenaar P, Chen L, Semmler AB, Parsonage WA, Kaumann AJ, (2007). Human heart β-adrenoceptors: β1-adrenoceptor diversification through 'affinity states' and polymorphism. Clin Exp Pharmacol Physiol 34: 1020-1028.
30. Pak MD, Fishman PH, (1996). Anomalous behavior of CGP 12177A on β1-adrenergic receptors. J Recept Signal Transduct Res 16: 1-23.
31. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
32. Rayo J, Amara N, Krief P, Meijler MM, (2011). Live cell labeling of native intracellular bacterial receptors using aniline-catalyzed oxime ligation. J Am Chem Soc 133: 7469-7475.
33. Rose RH, Briddon SJ, Hill SJ, (2012). A novel fluorescent histamine H1 receptor antagonist demonstrates the advantage of using fluorescence correlation spectroscopy to study the binding of lipophilic ligands. Br J Pharmacol 165: 1789-1800.
34. Schneider E, Keller M, Brennauer A, Hoefelschweiger BK, Gross D, Wolfbeis OS, et al. (2007). Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist. Chembiochem 8: 1981-1988.
35. Sillence MN, Hooper J, Zhou GH, Liu Q, Munn KJ, (2005). Characterization of porcine β1- and β2-adrenergic receptors in heart, skeletal muscle, and adipose tissue, and the identification of an atypical beta-adrenergic binding site. J Anim Sci 83: 2339-2348.
36. Staehelin M, Simons P, Jaeggi K, Wigger N, (1983). CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem 258: 3496-3502.
37. Stephenson RP, (1956). A modification of receptor theory. Br J Pharmacol Chemother 11: 379-393.
38. Stoddart LA, Vernall AJ, Denman JL, Briddon SJ, Kellam B, Hill SJ, (2012). Fragment screening at adenosine-A3 receptors in living cells using a fluorescence-based binding assay. Chem Biol 19: 1105-1115.
39. Vernall AJ, Stoddart LA, Briddon SJ, Hill SJ, Kellam B, (2012). Highly potent and selective fluorescent antagonists of the human adenosine A3 receptor based on the 1,2,4-triazolo[4,3-a]quinoxalin-1-one scaffold. J Med Chem 55: 1771-1782.
40. Ying LQ, Branchaud BP, (2011). Selective labeling and monitoring pH changes of lysosomes in living cells with fluorogenic pH sensors. Bioorg Med Chem Lett 21: 3546-3549.